Promethera Biosciences

Promethera Biosciences is a biopharmaceutical firm founded in 2009 with a mission to harness healthy human liver cells to develop innovative treatments for liver diseases. The company, originating from the Université Catholique de Louvain, focuses on crafting advanced treatments utilizing allogeneic adult stem cell technology. Their primary goal is the discovery, development, and commercialization of cell therapy products designed to treat liver diseases in an innovative manner through the use of allogenic progenitor cells derived from healthy human livers. Promethera Biosciences has recently garnered a substantial amount of attention in the investment community with a significant Series D investment of €7.50M on 16 December 2019. This investment was made by Pegasus Tech Ventures and Sony Innovation Fund, showcasing that the groundbreaking stem cell technology and innovative approach to treating liver diseases has attracted interest and support from notable investors. With a focus on biotechnology and the pharmaceutical industry, Promethera Biosciences is advancing two products based on a newly identified and patented progenitor cell type: the human Adult Liver-Derived Mesenchymal Progenitor Cell (hALDMSC). This not only demonstrates Promethera Biosciences' commitment to innovation but also underscores the potential of their technological advancements in the medical field.